Nantahala Capital Management LLC Takes Position in Inspire Medical Systems, Inc. $INSP

Nantahala Capital Management LLC bought a new position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 269,474 shares of the company’s stock, valued at approximately $12,021,235. Nantahala Capital Management LLC owned about 0.93% of Inspire Medical Systems as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. CWM LLC increased its holdings in Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after purchasing an additional 242 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after purchasing an additional 580 shares in the last quarter. Havemeyer Place LP purchased a new position in shares of Inspire Medical Systems during the 4th quarter valued at approximately $39,000. Smartleaf Asset Management LLC boosted its stake in shares of Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after buying an additional 205 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in shares of Inspire Medical Systems by 379.0% during the second quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock worth $43,000 after buying an additional 758 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Trading Up 1.1%

Shares of INSP opened at $61.49 on Friday. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of 13.31, a PEG ratio of 4.62 and a beta of 0.70. The stock has a 50 day moving average of $53.10 and a 200-day moving average of $52.50. Inspire Medical Systems, Inc. has a 52 week low of $38.91 and a 52 week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The business had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. During the same period in the prior year, the company posted $0.45 EPS. The business’s revenue was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, sell-side analysts predict that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Inspire Medical Systems news, insider Jason P. Kelly sold 963 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the sale, the insider directly owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

INSP has been the subject of a number of research analyst reports. Truist Financial restated a “hold” rating and issued a $62.00 price target (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Robert W. Baird increased their price objective on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Zacks Research raised shares of Inspire Medical Systems from a “hold” rating to a “strong-buy” rating in a report on Monday, August 17th. Mizuho boosted their target price on shares of Inspire Medical Systems from $55.00 to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. upped their target price on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $66.19.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.